4,342 reports of this reaction
3.9% of all UPADACITINIB reports
#2 most reported adverse reaction
ARTHRALGIA is the #2 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 4,342 FDA adverse event reports linking UPADACITINIB to ARTHRALGIA. This represents approximately 3.9% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among UPADACITINIB users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 4,342 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.9% of all adverse event reports for UPADACITINIB, making it one of the most commonly reported side effect.
If you experience arthralgia while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.